Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | IAPP | P10997 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26224365 | 0.87 | CYP1A2 (0.42) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2B6 | |
| SCHEMBL26224379 | 0.86 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2B6 | |
| SCHEMBL26224339 | 0.80 | PPARA (0.55) | PPARGPPARA | |
| SCHEMBL26224382 | 0.80 | CNR2 (0.38) | — | |
| SCHEMBL26224369 | 0.75 | CNR1 (0.40) | — | |
| SCHEMBL29307149 | 0.74 | CYP4F2 (0.36) | ALOX5PPARGPPARACYP4F2CYP4A11 | |
| SCHEMBL27064508 | 0.74 | TTR (0.35) | ALOX5PPARGPPARACYP4F2CYP4A11 | |
| SCHEMBL25122727 | 0.73 | PPARG (0.40) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2B6 | |
| SCHEMBL26224350 | 0.72 | LTB4R (0.41) | ALOX5PPARGPPARAIAPPCYP4F2 | |
| SCHEMBL4736045 | 0.72 | CYP3A4 (0.74) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | CYP1A2 486/4885CYP3A4 143/4885CYP2C8 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.